Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally-Advanced Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07390838
What this trial is testing

SH009 Injection in Patients With Advanced Solid Tumors.

Who this might be right for
Liver Cancer (Locally Advanced or Metastatic)Lung Cancer (NSCLC)Head and Neck Cancer Squamous Cell Carcinoma+4 more
Nanjing Sanhome Pharmaceutical, Co., Ltd. 150
Not applicableApproved For MarketingNCT01649284
What this trial is testing

Afatinib Expanded Access Program

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Testing effectiveness (Phase 2)UnknownNCT05519293
What this trial is testing

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
RedCloud Bio 76
Testing effectiveness (Phase 2)Ended earlyNCT02546986
What this trial is testing

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Celgene 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04035486
What this trial is testing

Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 587
Not applicableStudy completedNCT05862194
What this trial is testing

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Yuhan Corporation 534
Early research (Phase 1)Looking for participantsNCT04297605
What this trial is testing

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Who this might be right for
Non-small Cell Lung Cancer
University of Rochester 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07742956
What this trial is testing

Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Shanghai Allink Biotherapeutics Co., Ltd. 156
Large-scale testing (Phase 3)Study completedNCT04923945
What this trial is testing

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Hutchison Medipharma Limited 203
Testing effectiveness (Phase 2)Study completedNCT02917993
What this trial is testing

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Incyte Corporation 59
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Not applicableActive Not RecruitingNCT05103605
What this trial is testing

Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 274
Early research (Phase 1)Ended earlyNCT05061537
What this trial is testing

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Who this might be right for
Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more
Pfizer 13
Early research (Phase 1)Not Yet RecruitingNCT07675876
What this trial is testing

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer

Who this might be right for
Locally Advanced Non-Small Cell Lung CancerLung Adenocarcinoma
Carcinex Inc 10
Large-scale testing (Phase 3)Looking for participantsNCT07174908
What this trial is testing

IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd. 400
Not applicableNot Yet RecruitingNCT06786208
What this trial is testing

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Who this might be right for
Non Small Cell Lung Cancer
Henan Cancer Hospital 55
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Large-scale testing (Phase 3)Not Yet RecruitingNCT07829549
What this trial is testing

Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Who this might be right for
Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
RemeGen Co., Ltd. 540
Early research (Phase 1)Ended earlyNCT02387125
What this trial is testing

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Who this might be right for
SarcomaMelanomaNon-small Cell Lung Cancer+1 more
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 79
Testing effectiveness (Phase 2)Study completedNCT05014815
What this trial is testing

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)Nonsmall Cell Lung Cancer, Stage IIIBNonsmall Cell Lung Cancer, Stage IV
BeiGene 272
Next Page